Immunic, Inc. (IMUX)

Immunic, Inc. (IMUX) — VMCI valuation read

Headline read on IMUX: VMCI of 38/100 versus a Healthcare sector median of 50. The 12-point below-median position is what makes Immunic, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on IMUX: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on IMUX: value (IMUX trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -0.7x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

IMUX fell 2.7% over the trailing 7 days, with a -1.4% read on a 30-day basis.